MAP3K9

MAP3K9

An oncogene on chromosome 14q24.3-q31 that encodes a MAPK kinase kinase belonging to a protein kinase signal transduction cascade. MAP3K9 acts as an upstream activator of the JNK signal transduction cascade by phosphorylating MAP2K4/MKK4 and MAP2K7/MKK7; the JNK signalling pathway regulates stress response via activator protein-1 (JUN) and GATA4 transcription factors. MAP3K9 also plays a role in mitochondrial death signalling pathway, including cytochrome c release, which triggers apoptosis.

Each mitogen-activated protein kinase (MAPK) pathway is a conserved cascade of three protein kinases: an activated MAPK kinase kinase (MAPKKK) phosphorylates and activates a specific MAPK kinase (MAPKK), which in turn activates a specific MAPK.

Molecular pathology
MAP3K9 may play a role in oesophageal cancer susceptibility and/or pathogenesis.
References in periodicals archive ?
The trial, conducted by deCODE under a research collaboration and licensing agreement with Cephalon, was based upon deCODE's discovery of variants in the gene encoding the MAP3K9 kinase as risk factors for the development of asthma.
25) Deletion of chromosome 14 extending from the q24 to q31 band encompasses additional candidate genes involved in tumorigenesis, including SEL1L (the human ortholog of the C elegans sel-1 suppressor enhancer of lin-12), CHES1 (checkpoint suppressor 1), and MAP3K9 (mitogen activated protein kinase kinase kinase 9) genes.
The compound, developed by this third party originally for a different indication, is an inhibitor of the MAP3K9 kinase, the product of a gene deCODE has linked to risk of asthma.
The company is conducting a Phase II clinical trial in asthma of a third-party compound that inhibits the MAP3K9 kinase, the product of a gene deCODE has linked to risk of asthma.